CC
CLVS

Casdin Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Casdin Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-235,000
Closed -$6.9M – 38
2018
Q3 		$6.9M Buy
235,000
+15,000
+7% +$581K 0.84% 28
2018
Q2 		$10M Buy
220,000
+42,500
+24% +$2.07M 1.4% 24
2018
Q1 		$9.37M Buy
177,500
+50,000
+39% +$2.92M 1.65% 22
2017
Q4 		$8.67M Hold
127,500
– – 2.11% 19
2017
Q3 		$10.5M Sell
127,500
-2,500
-2% -$198K 2.97% 17
2017
Q2 		$12.2M Buy
130,000
+107,000
+465% +$6.55M 4.5% 8
2017
Q1 		$1.46M Buy
+23,000
New +$1.4M 0.86% 27
2016
Q4 		– Sell
-110,000
Closed -$3.97M – 29
2016
Q3 		$3.97M Sell
110,000
-40,000
-27% -$858K 3.21% 12
2016
Q2 		$2.06M Buy
+150,000
New +$2.19M 2.05% 17

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Casdin Capital's CLVS Position: Q4 2018 in Review

Casdin Capital sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 235,000 shares — an estimated $6.9M sold.

Casdin Capital first reported a position in CLVS in Q2 2016 and held it in 9 quarters. The position peaked at $12.2M in Q2 2017. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

  • Casdin Capital reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
  • Casdin Capital sold 235,000 Clovis Oncology, Inc. shares in Q4 2018, an estimated $6.9M.
  • Casdin Capital first reported a position in Clovis Oncology, Inc. in Q2 2016 and held it in 9 quarters.
  • Casdin Capital's Clovis Oncology, Inc. position peaked at $12.2M in Q2 2017.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Casdin Capital's 13F filing for Q4 2018, filed 13 Feb 2019.